{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:23:39Z","timestamp":1762507419361},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jpba.2018.05.028","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T12:39:56Z","timestamp":1526992796000},"page":"88-93","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits"],"prefix":"10.1016","volume":"158","author":[{"given":"Noha N.","family":"Atia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa R.","family":"El-Shaboury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia M.","family":"El-Gizawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Nabil","family":"Abo-Zeid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2018.05.028_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"3","author":"Sulkowski","year":"2014","journal-title":"N. Engl. J. Med. Orig."},{"key":"10.1016\/j.jpba.2018.05.028_bib0010","series-title":"Sovaldi (sofosbuvir): Summary of Product Characteristics","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.jpba.2018.05.028_bib0015","first-page":"243","article-title":"Hepatitis C virus therapyupdate 2013","volume":"29","author":"Casey","year":"2013","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.jpba.2018.05.028_bib0020","first-page":"17","article-title":"Hepatitis C infection in Egypt: prevalence, impact and management strategies, Hepatic Med","volume":"9","author":"Gomaa","year":"2017","journal-title":"Evid. Res."},{"key":"10.1016\/j.jpba.2018.05.028_bib0025","series-title":"Hepatology at a Glance","author":"Joshi","year":"2015"},{"key":"10.1016\/j.jpba.2018.05.028_bib0030","first-page":"316","article-title":"Hepatitis C in a new era: a review of current therapies","volume":"42","author":"Kish","year":"2017","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.jpba.2018.05.028_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jceh.2017.06.006","article-title":"Effect of sofosbuvir plus daclatasvir in hepatitis C virus genotype-4 patients: promising effect on liver fibrosis","volume":"8","author":"Abdel-Aziz","year":"2018","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.jpba.2018.05.028_bib0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ebiom.2017.05.011","article-title":"Response tailored protocol versus the fixed 12 weeks of dual Sofosbuvir\/Daclatasvir treatment in egyptian patients with chronic hepatitis C genotype-4 infection: a randomized, open-label, non-inferiority trial","volume":"21","author":"Yakoot","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jpba.2018.05.028_bib0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/17474124.2017.1326816","article-title":"Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients","volume":"11","author":"Elsharkawy","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpba.2018.05.028_bib0050","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2018.05.028_bib0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpba.2018.01.038","article-title":"Ultrasensitive spectrofluorimetric method for rapid determination of daclatasvir and ledipasvir in human plasma and pharmaceutical formulations","volume":"152","author":"Abo-Zeid","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.05.028_bib0060","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jpba.2018.04.049","article-title":"Efficient HPTLC-dual wavelength spectrodensitometric method for simultaneous determination of sofosbuvir and daclatasvir: biological and pharmaceutical analysis","volume":"156","author":"Abo-Zeid","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.05.028_bib0065","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2174\/1573412913666170210151615","article-title":"Validated spectrodensitometric method for simultaneous estimation of sofosbuvir, ribavirin and saxagliptin in their pure and pharmaceutical dosage forms","volume":"14","author":"El-shaboury","year":"2018","journal-title":"Curr. Pharm. Anal."},{"key":"10.1016\/j.jpba.2018.05.028_bib0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpba.2016.05.016","article-title":"Development and validation of sensitive and rapid UPLC-MS\/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study","volume":"128","author":"Rezk","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.05.028_bib0075","doi-asserted-by":"crossref","first-page":"e4186","DOI":"10.1002\/bmc.4186","article-title":"Development and validation of LC-MS\/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: application to pharmacokinetic study","author":"Abdallah","year":"2018","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2018.05.028_bib0080","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jchromb.2017.12.018","article-title":"UPLC?MS\/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV\/HCV co-infected patients","volume":"1073","author":"Notari","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.05.028_bib0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchromb.2015.08.038","article-title":"A. rong Hu, D. Gan, Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS\/MS","volume":"1002","author":"Shi","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.05.028_bib0090","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bmc.3690","article-title":"Novel and sensitive UPLC\u2013MS\/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study","volume":"30","author":"Rezk","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2018.05.028_bib0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpba.2015.01.027","article-title":"Multiplexed LC-MS\/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma","volume":"107","author":"Jiang","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.05.028_bib0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC\u2013MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.05.028_bib0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jchromb.2016.06.004","article-title":"Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS\/MS method: application to fasting and fed bioequivalence studies","volume":"1028","author":"Rezk","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.05.028_bib0110","year":"2005","journal-title":"International Conference on Harmonization, Topic Q2 (R1) Validation of Analytical Procedures: Text and Methodology"},{"key":"10.1016\/j.jpba.2018.05.028_bib0115","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.jpba.2018.05.028_bib0120","series-title":"Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products \u2014 General Considerations","author":"Food and Drug Administration","year":"2003"},{"key":"10.1016\/j.jpba.2018.05.028_bib0125","first-page":"31","article-title":"How to choose drug dosage for human experiments based on drug dose used on animal experiments: a review","volume":"1","author":"Rajasekaran","year":"2014","journal-title":"IJSS Case Reports Rev."},{"key":"10.1016\/j.jpba.2018.05.028_bib0130","series-title":"The Blood Morphology of Laboratory Animals","author":"Schermer","year":"1968"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518303790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518303790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T11:03:29Z","timestamp":1563966209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518303790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":26,"alternative-id":["S0731708518303790"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.05.028","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}